Loss of these properties in the small molecule JMJD1A inhibitor DMOG treated NB cell lines, suggests that MYCN target genes could be used as potential therapeutic targets in the treatment of neuroblastoma. This evidence concerns the gene KDM3A and neuroblastoma.